Evolus, Inc. (NASDAQ:EOLS) Director Buys $189,000.00 in Stock

Evolus, Inc. (NASDAQ:EOLS) Director Albert G. White III acquired 20,000 shares of the stock in a transaction dated Monday, June 9th. The shares were bought at an average price of $9.45 per share, for a total transaction of $189,000.00. Following the transaction, the director now owns 50,378 shares in the company, valued at approximately $476,072.10. This represents a 65.84% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Evolus Price Performance

Shares of NASDAQ:EOLS opened at $10.18 on Friday. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The stock has a market cap of $656.37 million, a PE ratio of -11.19 and a beta of 1.00. The company’s fifty day moving average is $10.30 and its 200 day moving average is $11.82. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Tang Capital Management LLC boosted its holdings in Evolus by 3.1% during the 4th quarter. Tang Capital Management LLC now owns 4,997,399 shares of the company’s stock valued at $55,171,000 after acquiring an additional 150,000 shares during the period. Vanguard Group Inc. lifted its position in Evolus by 2.0% in the first quarter. Vanguard Group Inc. now owns 3,234,068 shares of the company’s stock valued at $38,906,000 after purchasing an additional 62,664 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Evolus by 10.8% during the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock valued at $34,557,000 after purchasing an additional 305,300 shares during the period. Caligan Partners LP boosted its stake in shares of Evolus by 22.7% during the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after purchasing an additional 498,900 shares during the period. Finally, Millennium Management LLC grew its holdings in shares of Evolus by 1.7% in the first quarter. Millennium Management LLC now owns 1,392,028 shares of the company’s stock worth $16,746,000 after purchasing an additional 23,605 shares during the last quarter. 90.69% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several research analysts recently issued reports on EOLS shares. BTIG Research started coverage on Evolus in a research note on Thursday, April 17th. They issued a “buy” rating and a $21.00 target price on the stock. Needham & Company LLC reaffirmed a “buy” rating and set a $22.00 price target on shares of Evolus in a research note on Thursday, May 8th. Barclays increased their price objective on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research report on Wednesday, March 5th. Finally, HC Wainwright reissued a “buy” rating and set a $27.00 price objective on shares of Evolus in a report on Thursday, April 10th. Five equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $23.75.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.